NLR–FAR Index as a Prognostic Marker in Acute Ischemic Stroke: Biological Rationale, Current Evidence, and Clinical Translation (2015–2025)
International Journal of Medicine · 25.04.2025 · 7 (6) · 16-31
DOI: 10.61336/im/25-06-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Medicine, online erschienen am 25.04.2025. Verfasst von Mohammed Abdul Muqeeth.
Themen: Schlaganfall
Abstract (Originalsprache)
Background
Acute ischemic stroke (AIS) is a leading cause of mortality and long-term disability worldwide. Early identification of patients at high risk of unfavorable functional outcomes, hemorrhagic transformation, and mortality remains central to acute stroke management. Readily available blood-derived biomarkers that reflect inflammation, coagulation, endothelial dysfunction, and systemic physiological reserve have therefore attracted growing interest. Among these, the neutrophil-to-lymphocyte ratio (NLR) and fibrinogen-to-albumin ratio (FAR) have individually emerged as promising prognostic markers in AIS. More recently, a composite NLR–FAR index has been proposed as a potentially superior integrative biomarker.
Objective
To critically review the biological rationale, clinical evidence, and translational potential of the NLR–FAR index as a prognostic marker in patients with AIS.
Discussion
This review evaluates the pathobiological basis linking neutrophil-driven inflammation, lymphocyte suppression, fibrinogen-mediated thromboinflammation, and hypoalbuminemia to ischemic brain injury. It synthesizes evidence from 2015–2025 on NLR and FAR individually, examines the emerging but still sparse data on the combined NLR–FAR index, and compares this marker with other inflammatory and hemostatic biomarkers used in stroke prognostication. Major findings: NLR consistently correlates with baseline stroke severity, poor 3-month functional outcome, symptomatic intracranial hemorrhage, and mortality across observational studies and meta-analyses, especially in reperfusion-treated cohorts. FAR also shows growing evidence for association with poor functional outcome, hemorrhagic transformation, and adverse outcomes after intravenous thrombolysis and endovascular therapy. However, direct evidence for the combined NLR–FAR index remains limited and is currently confined to a small number of recent retrospective studies, mainly in thrombectomy populations.
Conclusion
The NLR–FAR index is biologically plausible and clinically attractive as a low-cost, rapidly obtainable composite biomarker for early risk stratification in AIS. Nonetheless, current evidence remains preliminary. At present, NLR and FAR may be considered adjunctive prognostic markers, whereas the combined NLR–FAR index should be regarded as an emerging research tool requiring prospective validation, standardized calculation methods, and external multicenter confirmation before routine clinical implementation
Zitieren
APA
Muqeeth, M. A. (2025). NLR–FAR Index as a Prognostic Marker in Acute Ischemic Stroke: Biological Rationale, Current Evidence, and Clinical Translation (2015–2025). International Journal of Medicine, 7(6), 16-31. https://doi.org/10.61336/im/25-06-4
Vancouver
Muqeeth MA. NLR–FAR Index as a Prognostic Marker in Acute Ischemic Stroke: Biological Rationale, Current Evidence, and Clinical Translation (2015–2025). International Journal of Medicine. 2025;7(6):16-31. doi:10.61336/im/25-06-4
BibTeX
@article{Muqeeth2025,
author = {Muqeeth, Mohammed Abdul},
title = {NLR–FAR Index as a Prognostic Marker in Acute Ischemic Stroke: Biological Rationale, Current Evidence, and Clinical Translation (2015–2025)},
journal = {International Journal of Medicine},
year = {2025},
volume = {7},
number = {6},
pages = {16--31},
doi = {10.61336/im/25-06-4}
}
EUVIMED